View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
DOT/OST | RIN: 2105-AE58 | Publication ID: Spring 2017 |
Title: ●Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Addition of Certain Schedule II Drugs to the Department of Transportation's Drug-Testing Panel and Certain Minor Amendments | |
Abstract:
The rulemaking would harmonize the DOT drug-testing program regulations on urine testing with the revised Mandatory Guidelines established by the U.S. Department of Health and Human Services for Federal drug-testing programs. Specifically, this rulemaking would add hydrocodone, hydromorphone, oxymorphone, and oxycodone to its drug-testing panel; add methylenedioxyamphetamine (MDA) as an initial test analyte; and remove methylenedioxyethylamphetamine (MDEA) as a confirmatory test analyte. This rulemaking would also explore burden-reducing measures, including adding clarification to certain drug-testing program provisions, removing outdated information in the regulations that is no longer needed, and removing the requirement for employers and C/TPAs to submit blind specimens. |
|
Agency: Department of Transportation(DOT) | Priority: Substantive, Nonsignificant |
RIN Status: First time published in the Unified Agenda | Agenda Stage of Rulemaking: Long-Term Actions |
Major: No | Unfunded Mandates: No |
CFR Citation: 49 CFR 40 | |
Legal Authority: 40 U.S.C. 102,01, 322, 5331 40 U.S.C. 31306, and 54101 et seq. |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: No | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Information URL: www.regulations.gov | Public Comment URL: www.regulations.gov |
RIN Data Printed in the FR: No | |
Agency Contact: Bohdan Baczara Department of Transportation Office of the Secretary 1200 New Jersey Avenue SE, Washington, DC 20590 Phone:202 366-6364 Fax:202 366-3897 Email: bohdan.baczara@dot.gov |